Third Quarter Consolidated Revenues of 2.68billion,up7179 million and GAAP Net Income of 181millionConsolidatedAdjustedEBITDAAttributabletoBauschHealth(non−GAAP)1of986 million, including an $81 million acquired In-Process Research & Development ("IPR&D") charge, up 8% on a Reported basis over the prior year period BAUSCH HEALTH EXCLUDING BAUSCH + LOMB THI ...